Targeted therapies for use in clinical studies, such as those in immuno-oncology (I-O), are both the source of medical breakthroughs and the future of pharmaceuticals. Flow cytometry is a critical tool in employing these therapies, because it can assess the efficacy and safety of these molecules by giving us insight into how they interact with living cells on a cellular level.

Despite the availability of off-the-shelf flow cytometry assays, detecting the presence of complex molecules requires custom flow cytometric assays specific to these molecular targets. As a result, many sponsors do not have the resources required to develop customised assays in-house, requiring a partner with the expertise to consult the needs of their trial.

In our whitepaper, “Driving Clinical Trials Forward: The Benefits of Establishing a Strategic Partnership for Flow Cytometry,” we explore:

• Best practices in developing and implementing customised flow cytometric assays for clinical research
• The benefits of adopting a strategic partner in a CRO to perform these complex assays